Table 3 In-hospital results and clinical outcomes.

From: Results of streamlining TAVR procedure towards a minimalist approach: a single center experience in Taiwan

 

GA group (N = 48)

LACS group 1 (N = 50)

LACS group 2 (N = 125)

P value

ICU stay (days)

2 (1–5)

2 (1–3)*

1 (1–1)*†

0.0001

Hospital stay (days)

9 (7–13)

8 (6–11)

6 (5–9)*†

0.0001

Hospital acquired pneumonia

6 (12.5%)

3 (6.0%)

7 (5.6%)

0.427

In-hospital GI bleeding

5 (10.4%)

2 (4.0%)

4 (3.2%)

0.235

In-hospital AKI

4 (8.3%)

2 (4.0%)

13 (10.4%)

0.66

In-hospital stroke

1 (2.1%)

1 (2.0%)

2 (1.6%)

0.829

Post-TAVR PPM

10 (20.8%)

11 (22.0%)

17 (13.6%)

0.147

Medical fee reimbursed during hospitalization (NT dollars)a

267,906 (193,116–380,331)

209,398 (151,889–314,497)*

190,945 (111,713–296,163)*

0.0079

30-day mortality

0 (0.0%)

0 (0.0%)

4 (3.2%)

0.42

  1. ICU and Hospital stay, medical fee reimbursed during hospitalization were presented with median and interquartile range.
  2. GA general anesthesia, LACS local anesthesia or consciousness sedation, ICU intensive-care unit, GI bleeding gastro-intestinal bleeding, AKI acute kidney injury, TAVR transcatheter aortic valve replacement, PPM permanent pacemaker, NT dollars New-Taiwan dollars.
  3. *Adjusted P < 0.05 as compared to GA group.
  4. †Adjusted P < 0.05 as compared to LACS group 1.
  5. aIncluding medical fee of TAVR procedure, medication, hospitalization, and devices other than transcatheter heart valve.
Back to article page